Appearance:White to grayish white crystalline powder
Synopsis：Eplerenone, a new selective aldosterone receptor antagonist, was approved by the State Food and Drug Administration for clinical application in 2002. It has a stronger antagonistic effect on aldosterone than spironolactone, and has a very low affinity for androgen and progesterone receptors. It has a definite curative effect on the treatment of high blood pressure, heart failure and myocardial infarction with less adverse reactions and good tolerance, It is a good substitute for spironolactone. For severe hypertension which can not be controlled by combination of antihypertensive drugs, eplerenone can significantly reduce blood pressure, especially systolic blood pressure. It is closely related to angiotensin converting enzyme inhibitor (ACEI) and β Receptor blockers can improve the quality of life and reduce mortality in patients with severe heart failure and myocardial infarction.
Structural formula:
Properties
Summary
Eplerenone, a new selective aldosterone receptor antagonist, was approved by the State Food and Drug Administration for clinical application in 2002. It has a stronger antagonistic effect on aldosterone than spironolactone, and has a very low affinity for androgen and progesterone receptors. It has a definite curative effect on the treatment of high blood pressure, heart failure and myocardial infarction with less adverse reactions and good tolerance, It is a good substitute for spironolactone. For severe hypertension which can not be controlled by combination of antihypertensive drugs, eplerenone can significantly reduce blood pressure, especially systolic blood pressure. It is closely related to angiotensin converting enzyme inhibitor (ACEI) and β Receptor blockers can improve the quality of life and reduce mortality in patients with severe heart failure and myocardial infarction.
Manufacturing
